Insider Transactions in Q4 2021 at Atara Biotherapeutics, Inc. (ATRA)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2021
|
Jakob Dupont EVP, Head of R&D |
SELL
Open market or private sale
|
Direct |
5,000
-5.23%
|
$85,000
$17.94 P/Share
|
|
Dec 01
2021
|
Jakob Dupont EVP, Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.97%
|
$45,000
$9.58 P/Share
|
|
Nov 16
2021
|
Jakob Dupont EVP, Head of R&D |
SELL
Open market or private sale
|
Direct |
2,199
-2.37%
|
$37,383
$17.12 P/Share
|
|
Nov 16
2021
|
Utpal Koppikar Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,655
-2.27%
|
$62,135
$17.12 P/Share
|
|
Nov 16
2021
|
Amar Murugan EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,124
-2.37%
|
$36,108
$17.12 P/Share
|
|
Nov 16
2021
|
Joe Newell Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
3,332
-2.86%
|
$56,644
$17.12 P/Share
|
|
Nov 16
2021
|
Pascal Touchon President and CEO |
SELL
Open market or private sale
|
Direct |
8,402
-2.49%
|
$142,834
$17.12 P/Share
|
|
Nov 15
2021
|
Joe Newell Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
7,000
-5.67%
|
$119,000
$17.71 P/Share
|
|
Nov 15
2021
|
Joe Newell Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+2.76%
|
$42,000
$12.15 P/Share
|
|
Nov 04
2021
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
13,354
-29.77%
|
$253,726
$19.5 P/Share
|
|
Nov 02
2021
|
Jakob Dupont EVP, Head of R&D |
SELL
Open market or private sale
|
Direct |
5,000
-5.11%
|
$80,000
$16.41 P/Share
|
|
Nov 02
2021
|
Jakob Dupont EVP, Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$45,000
$9.58 P/Share
|